TY - JOUR
T1 - Systematic reviews of antihypertensive drugs
T2 - A review of publication trends, characteristics, and quality
AU - Esam, Hariprasad
AU - Kanukula, Raju
AU - Dhurjati, Rupasvi
AU - Aerram, Rupa
AU - Chevireddy, Sindhujareddy
AU - Bhaumik, Soumyadeep
AU - Atkins, Emily
AU - Huffman, Mark D.
AU - Rodgers, Anthony
AU - Salam, Abdul
N1 - Publisher Copyright:
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
PY - 2021/5
Y1 - 2021/5
N2 - This review presents publication trends, characteristics, and quality of systematic reviews (SRs) of randomized controlled trials (RCTs) of antihypertensive drugs (AHTDs). Between 1985 and 2017, 1,173 SRs were published, and in the last 20 years, 10, 35, and 116 were published in the year 1996, 2006, and 2016, respectively. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers were the most common class of drugs studied. Fourteen percent of the SRs were prospectively registered/published protocol. Three-fourth of the SRs did not report a full search strategy, and 45% did not report a PRISMA or similar diagram. Of the 34 SRs published in the five high impact factor journals in the last 10 years, 15%, 21%, and 65% have unclear, low, and high risk of bias, respectively. There has been a steady increase in the publication of SRs of RCTs of AHTDs. However, adherence to standard methods of conduct and reporting continues to be low.
AB - This review presents publication trends, characteristics, and quality of systematic reviews (SRs) of randomized controlled trials (RCTs) of antihypertensive drugs (AHTDs). Between 1985 and 2017, 1,173 SRs were published, and in the last 20 years, 10, 35, and 116 were published in the year 1996, 2006, and 2016, respectively. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers were the most common class of drugs studied. Fourteen percent of the SRs were prospectively registered/published protocol. Three-fourth of the SRs did not report a full search strategy, and 45% did not report a PRISMA or similar diagram. Of the 34 SRs published in the five high impact factor journals in the last 10 years, 15%, 21%, and 65% have unclear, low, and high risk of bias, respectively. There has been a steady increase in the publication of SRs of RCTs of AHTDs. However, adherence to standard methods of conduct and reporting continues to be low.
KW - antihypertensive agents
KW - mapping review
KW - risk of bias
KW - systematic reviews
UR - http://www.scopus.com/inward/record.url?scp=85101919945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101919945&partnerID=8YFLogxK
U2 - 10.1111/jch.14216
DO - 10.1111/jch.14216
M3 - Review article
C2 - 33650776
AN - SCOPUS:85101919945
SN - 1524-6175
VL - 23
SP - 915
EP - 922
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 5
ER -
